Neutrophil‐to‐lymphocyte ratio at the start of the second course of durvalumab plus tremelimumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: A multicenter analysis
Rattachement africain : jp. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND AND AIMS: Durvalumab plus tremelimumab (Dur/Tre) therapy is expected to have good therapeutic efficacy for patients with unresectable hepatocellular carcinoma (u-HCC). We previously reported that the neutrophil-to-lymphocyte ratio (NLR) during atezolizumab plus bevacizumab therapy in u-HCC patients was a useful marker for predicting the therapeutic response. Therefore, we investigated whether the NLR during Dur/Tre therapy could predict treatment outcomes in patients with u-HCC. DESIGN: The present study included 64 u-HCC patients treated with Dur/Tre and evaluated for their initial response by dynamic computed tomography or magnetic resonance imaging at least once until December 2024. Alpha-fetoprotein (AFP) and des-gamma-carboxyprothrombin (DCP) ratios were defined as follows: the pretreatment levels of AFP and DCP were set to 1, and the AFP and DCP ratios to pretreatment were calculated at the start of the second course of Dur/Tre therapy. RESULTS: Of the 64 HCC patients, 34 patients (53%) achieved a disease control rate (non-PD) at the initial evaluation. The NLR at the start of the second course (NLR-2c) tended to be lower in patients with non-PD than progressive disease (p = 0.133), and the optimal cutoff value was 5.75. Patients with NLR-2c ≥ 5.75 had a shorter progression-free survival (PFS) than those with NLR-2c < 5.75 (median: 1.7 vs. 5.5 months, p = 0.002). Multivariate analysis showed that NLR-2c ≥ 5.75 (HR 4.66; p < 0.001) and AFP ratio ≥ 0.933 (HR 4.32; p = 0.004) were significantly associated with poor PFS. CONCLUSIONS: The NLR-2c value is useful for predicting PFS in u-HCC patients treated with Dur/Tre therapy.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Neutrophil‐to‐lymphocyte ratio at the start of the second course of durvalumab plus tremelimumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: A multicenter analysis
- Date Crossref
- 28/03/2025
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Nagoya City University Department of Gastroenterology and Metabolism pays non établi dans la noticeUniversité ou école supérieure
-
Kasugai Municipal Hospital Department of Gastroenterology pays non établi dans la noticeÉtablissement de santé
-
Japanese Red Cross Nagoya Daini Hospital pays non établi dans la noticeÉtablissement de santé
-
Nagoya Medical Center pays non établi dans la noticeÉtablissement de santé
-
Toyokawa City Hospital Department of Gastroenterology pays non établi dans la noticeÉtablissement de santé
-
Gifu Prefectural Tajimi Hospital Department of Gastroenterology pays non établi dans la noticeÉtablissement de santé
-
Nagasaki Rousai Hospital pays non établi dans la noticeÉtablissement de santé
-
Kumamoto University pays non établi dans la noticeUniversité ou école supérieure
-
Department of Gastroenterology Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital Nagoya Japan Department of Gastroenterology pays non établi dans la noticeÉtablissement de santé
-
Department of Gastroenterology Nagoya City East Medical Center Nagoya Japan Department of Gastroenterology pays non établi dans la noticeÉtablissement de santé
-
Department of Gastroenterology Asahi Rousai Hospital Owariasahi Japan Department of Gastroenterology pays non établi dans la noticeÉtablissement de santé
-
Faculty of Life Sciences Department of Gastroenterology and Hepatology pays non établi dans la noticeUniversité ou école supérieure
Department of Gastroenterology and Metabolism — Nagoya City University, Department of Gastroenterology — Kasugai Municipal Hospital et Japanese Red Cross Nagoya Daini Hospital, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.